# CBX-250

Source: https://onco.cc/drugs/cbx-250/  
OnCo record `cbx-250` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CBX-250 is an experimental TCR-mimetic T cell engager from Crossbow Therapeutics, in phase 1 trials for relapsed or refractory acute myeloid leukaemia, higher-risk myelodysplastic syndrome and chronic myelomonocytic leukaemia and other cancers.

## Summary

CBX-250 is a TCR-mimetic T cell engager (T-Bolt) from Crossbow Therapeutics. A T cell engager whose TCR-mimetic antibody arm recognises a cathepsin G peptide presented on HLA, abundant on leukaemia cells but not normal cells, and pulls T cells onto them. Given under the skin. Its furthest stage is phase 1, for relapsed or refractory acute myeloid leukaemia, higher-risk myelodysplastic syndrome, chronic myelomonocytic leukaemia and chronic myeloid leukaemia. ClinicalTrials.gov registers it in one study linked below. CROSSCHECK-001 phase 1 NCT06994676 recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: CBX-250
- Modality: TCR-mimetic T cell engager (T-Bolt)
- Mechanism: A T cell engager whose TCR-mimetic antibody arm recognises a cathepsin G peptide presented on HLA, abundant on leukaemia cells but not normal cells, and pulls T cells onto them. Given under the skin.

## Sources

- Crossbow Therapeutics: crossbowtx.com: https://www.crossbowtx.com/press-release-09-16-25
- Crossbow Therapeutics: crossbowtx.com: https://www.crossbowtx.com/
- Crossbow Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06994676
- ClinicalTrials.gov: trials of CBX-250: https://clinicaltrials.gov/search?intr=CBX-250

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/), [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/)
- companies: [Crossbow Therapeutics](https://onco.cc/companies/crossbow-therapeutics/)
- trials: [A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias](https://onco.cc/trials/nct06994676/)

---
JSON: https://onco.cc/api/v1/entities/cbx-250.json